Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations

This facility manufactures APIs & formulations of oncology and non-oncology products.

Briefs: Sun Pharma and Kimia Biosciences

Sun Pharma's Dadra facility receives OAI status from US FDA

Merck India appoints Dhananjay Singh as MD Merck Life Science in India

CRISPR-based innovations drive $21 billion in pharmaceutical licensing deals over five years, reveals GlobalData

The period from 2020 to 2022 witnessed a remarkable surge in deal worth

Generics gain ground, yet HCPs still favor branded drugs, finds GlobalData

A significant proportion of healthcare professionals still tend to favor branded drugs

Pfizer announces positive results from Phase 3 Study of Abrysvo

ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.

KRAZATI in Combination with Cetuximab demonstrates targeted treatment option for KRAS G12C- colorectal cancer

Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program

Syntegon showcases oral solid dosage portfolio at Achema

Fluid bed processes: drying, granulating, and coating in just one product container

Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer

Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2

Shivalik Rasayan’s API facility gets 7 observations from USFDA

These observations are procedural in nature and will be responded within the stipulated time